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Background: The roles of microphthalmia-associated transcription factor (Mitf) in the 
skeletal muscle and during myogenesis are unclear. 
Methods: Expression of Mitf in mouse tissues and during myogenesis was evaluated. 
Effects of Mitf knockdown on myogenesis and gene expression related to myogenesis 
were subsequently explored. Furthermore, effects of p21, a cyclin-dependent kinase 
inhibitor, and integrin 9 (Itga9) were examined. 
Results: Mitf was highly expressed in the skeletal muscle; Mitf-A and -J were expressed. 
Mitf expression increased after differentiation stimulation in C2C12 myogenic cells. 
Down-regulation of Mitf expression by transfection of siRNA for common Mitf 
inhibited myotube formation, which was reproduced by Mitf-A knockdown. 
Morphometric analyses indicated that both multinucleated cell number and the 
proportion of myotubes with more than 6 nuclei were decreased in Mitf-knockdown 
cells, suggesting that Mitf is required for not only the formation of nascent myotubes 
but also their maturation. Searching for genes positively regulated by Mitf revealed p21 
and Itga9; decreasing Mitf expression inhibited up-regulation of p21 expression after 
differentiation stimulation and blocked the induction of Itga9 expression in response to 
differentiation. Knockdown of p21 decreased the number of multinucleated cells, 
whereas Itga9 knockdown did not affect the myotube number. Both p21 knockdown 
and Itga9 knockdown decreased the proportion of myotubes with more than 6 nuclei. 
Conclusion: The present study clarified that Mitf is significantly expressed during 
myogenesis, and that Mitf is required for efficient myotube formation through 
expression of p21 and Itga9. 
General significance: Mitf positively regulates skeletal muscle formation. 
 





Skeletal muscle formation consists of a complex set of differentiation steps: 
commitment of mesenchymal stem cells to myoblast lineage cells, progression of 
differentiation with the expression of muscle-cell-specific proteins, and fusion of 
myoblasts into multinucleated myotubes. Mammalian myotube formation occurs in two 
phases [1, 2]. In the first phase, differentiated myoblasts fuse together to form small 
myotubes; to accomplish this process, proliferating myoblasts exit cell cycle, and some 
myoblasts undergo apoptosis. In the second phase, additional myoblasts subsequently 
fuse with myotubes to form large myotubes. Although the roles of myogenic regulatory 
factors (MRFs), including Myf5, Myod, Myogenin and Mrf4, in myogenic 
differentiation are unquestionable [3-5], a number of factors, such as secreted proteins, 
membrane proteins and transcriptional regulators, are also involved in myogenesis [2]. 
 
Microphthalmia-associated transcription factor (Mitf) is a member of the basic 
helix-loop-helix leucine zipper (bHLH-LZ) family of transcription factors [6-8]. 
Expression levels of Mitf, evaluated by Western blotting and Northern blotting, vary 
among tissues; it is highly expressed in melanocytes, mast cells, osteoclasts, and the 
heart [9-11]. Thus, the roles of Mitf have been mainly examined in these cells [11-14], 
and Mitf activities in other tissues are largely unknown. Of the Mitf variants that are not 
the result of genetic mutation, nine Mitf isoforms have been identified in mice that differ 
in their transcriptional initiation site: Mitf-A, -B, -C, -D, -E, -H, -J, -M and -mc. The Mitf 
variants contain an isoform-specific first exon, while exons 2 to 9 of all Mitf isoforms 
examined to date are identical. Mitf isoforms are expressed in a cell type-specific 
manner, and their transcriptional activities are slightly but significantly different 
depending on the target gene [15-19]. In addition, two types of Mitf mRNAs with or 
without an 18-base insert (exon 6a) are generated by alternative use of the two acceptor 
sites located at the 5’ end of exon 6 in Mitf-A, -H, -J, -M and -mc [6, 9, 20, 21]. In the 
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present study, we show the relatively higher expression of Mitf-A in the skeletal muscle, 
and present the potential role of Mitf in the progression of myogenesis. 
 
 
Materials and methods 
Animals and cell culture 
Nine C57BL/6 mice aged 7-8 wk were used to examine the tissue distribution of Mitf. 
The experiment was approved by Azabu University Animal Experiment Committee. 
C2C12 myoblasts were obtained from the American Type Culture Collection (Rockville, 
MD). Cells were cultured in growth medium, i.e., Dulbecco’s modified Eagle’s medium 
(DMEM) with heat-inactivated 10% fetal bovine serum (FBS), 100 U/ml penicillin and 
100 g/ml streptomycin, at 37°C under a humidified 5% CO2 atmosphere. To induce 
differentiation from myoblasts to myotubes, the medium was replaced at confluence 
(day 0) with differentiation medium consisting of DMEM with 2% horse serum 
supplementing the antibiotics. To isolate myotubes, cells on day 7 were trypsinized for a 
short time under a microscope until detachment of multinucleated cells (2 min), 
followed by centrifugation to obtain a myotube-rich fraction. 
 
RT-PCR, restriction fragment length polymorphism and quantitative RT-PCR 
Total RNA isolation from tissues and cells, RT-PCR and restriction fragment length 
polymorphism (RFLP) were performed as described previously [21]. Quantitative 
RT-PCR (qRT-PCR) was carried out as described previously [22]. The used PCR 
primers in qRT-PCR are presented in Table 1. To compare tissue Mitf expression, the 
appropriate corrected gene was chosen using a mouse housekeeping gene primer set 
(TaKaRa, Otsu, Japan). The relative mRNA level was expressed as a ratio with -actin 
to evaluate tissue distribution and Gapdh was used as a reference gene to examine 





To examine expression of Mitf in the skeletal muscle, thigh muscle and heart as a 
positive control were homogenized in RIPA buffer. After 30 min on ice, the debris was 
removed by centrifugation at 2,500 × g for 2 min at 4ºC. After centrifugation at 
12,000 ×  g for 5 min at 4ºC, the supernatant was recovered and the protein 
concentration was measured by the bicinchoninic acid method [23]. Fifty g of the 
protein was loaded on 10% SDS-polyacrylamide gel. Western blotting was performed 
as described previously [24, 25]. Expression of Mitf and myosin heavy chain (Myhc) 
was examined by use of mouse monoclonal antibodies against Mitf (X1405M; Exalpha 
Biologicals) and Myhc (MY-32; Sigma), respectively. There are two types of muscle 
fiber, i.e., fast-twitch and slow-twitch; fast-twitch muscle fibers express Myhc2a, 
Myhc2b and Myhc2x, whreas slow-twitch muscle fibers do Myhc1 [26]. According to 
the manufacturer’s manual, this antibody for Myhc recognizes fast-type muscle fibers. 
After incubation of the membranes with ECL Advance reagent (GE Healthcare), the 
chemiluminescent signals were exposed to X-ray film. Subsequently, antibodies as well 
as the detection reagents were stripped and reprobed with anti--tubulin (ab11304; 
Abcam) or anti--actin antibody (AC-15; Abcam). 
 
Immunohistochemistry 
C2C12 cells were grown on glass chamber slides coated with type I collagen (Thermo 
Fisher Scientific) and were fixed with 3% paraformaldehyde in PBS for 30 min, 
followed by treatment with 1% Triton X-100 in PBS for 10 min. After washing with 
PBS, cells were incubated with 3% H2O2 to remove endogenous peroxidase. 
Subsequently, cells were treated with 1.5% normal goat serum in PBS for 20 min to 
block nonspecific reactions. Diluted mouse monoclonal antibody against Mitf 
(X1405M; Exalpha Biologicals) with 0.1% bovine serum albumin in PBS at 1 : 80 was 
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used to identify Mitf expression at the protein level. After incubation with the primary 
antibody for 2 h at room temperature, Mitf-positive cells were visualized using 
VECTASTAIN Elite ABC kit (Vector Laboratories) and 3,3’-diaminobenzidine (DAB; 
Dojindo) according to the manufacturer’s protocol. 
 
siRNA transfection 
To target the expression of common Mitf, Mitf-A or Itga9 and green fluorescent protein 
(GFP) controls, oligonucleotides for the respective genes were synthesized by BONAC 
corporation (Kurume, Japan) as follows: 5'-GAAACUUGAUCGACCUCUACA-3' and 
5'-UAGAGGUCGAUCAAGUUUCCA-3' for common Mitf, 5’- 
GGAGUCAUGCAGUCCGAAUTT -3’ and 5'- AUUCGGACUGCAUGACUCCTT -3' 
for Mitf-A, 5'-CCUUAGUGCUCUUCCGAAAGA-3' and 
5'-UUUCGGAAGAGCACUAAGGUU-3' for Itga9, and 
5’-GGUUACGUCCAGGAGCGCATT-3’ and 
5'-UGCGCUCCUGGACGUAGCCTT-3' for GFP. The siRNA for p21 was purchased 
(sc-29428; Santa Cruz Biotechnology). An equal amount of the oligonucleotide was 
mixed for each gene to prepare siRNA. Thirty picomoles of siRNA was transfected into 
C2C12 cells seeded at a density of 1.5  104 cells in 24-well plates every 48 h. siRNA 
was transfected using Lipofectamine RNAiMAX (Invitrogen) according to the 
manufacturer’s protocol. Antibiotics were not supplemented to the culture media in 
siRNA transfection experiments. 
 
Morphological analysis 
Cells were fixed with methanol for 2 min and subsequently stained with Giemsa 
staining for 20 min. Cells with more than 3 nuclei were judged as myotubes. Eight 
views per treatment in an experiment were analyzed. Experiments were repeated two or 





Proliferation of C2C12 cells was measured by a BrdU cell proliferation assay (Cell 




Data are presented as the mean  SE. Comparisons between groups were conducted 




Expression of Mitf in tissues and during myogenesis 
Tissue distribution of Mitf was quantified by qRT-PCR. First, the expressions of 12 
genes, Atp5f1, B2m, -actin, Gapdh, Hprt1, Pgk1, Ppia, RpLp1, Rps18, Tbp, Tfrc, and 
Ywhaz, were quantified for evaluation as appropriate corrected genes; quantitative PCR 
using cDNA prepared from equal amounts of total RNA revealed that -actin 
expression was the most stable among the tested tissues, which were evaluated by 
“geNorm” (http://medgen.ugent.be/~jvdesomp/genorm/) (data not shown). Thus, the 
gene transcript level of Mitf was corrected for that of -actin (Fig. 1A). Expression of 
Mitf was highest in the heart, as expected. Although Mitf is recognized as a 
tissue-restricted transcription factor [6-8], its expression was detected in a wide variety 
of tissues. In particular, expression in the skeletal muscle was relatively higher. 
Previous studies indicated Mitf expression in the skeletal muscle [9, 27], but the role of 
Mitf is not known. Thus, we characterized the expression and function of Mitf in the 
skeletal muscle and during myogenesis in detail. Examining Mitf isoforms differing in 
transcriptional initiation site in the skeletal muscle indicated that more than 99% of Mitf 
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was Mitf-A, and that Mitf-H and -J were also expressed significantly (Fig. 1B). 
 
In a C2C12 myotube differentiation model, C2C12 myoblasts fuse to form 
multinucleated myotube cells upon serum starvation on day 0 [28]. To evaluate gene 
expression in C2C12 cells, we chose Gapdh instead of -actin as a reference gene; 
qPCR using cDNA prepared from equal amount of total RNA indicated gradual 
decrease in -actin expression with progression of myogenesis, whereas expression of 
Gapdh was relatively constant (Supplementary Fig. 1). Total Mitf expression level 
increased up to day 8 and then reached a plateau (Fig. 1C). Similar to the expression 
pattern in the skeletal muscle, Mitf-A was the main isoform (59-76% of total Mitf). In 
addition, Mitf-J but not -H was expressed. The expression pattern of Mitf isoform was 
constant during myogenesis; the ratio of Mitf-A to Mitf-J was 1.5 to 3.2 : 1. Expression 
of Mitf in the skeletal muscle and C2C12 cells was also verified at the protein level by 
Western blot analyses (Fig. 1D). In addition, consistent with the changes at the mRNA 
level, expression of Mitf protein was increased after differentiation stimulation (Fig. 1E). 
Furthermore, Mitf was exclusively localized in the nucleus of C2C12 cells (Fig. 1F). 
We also examined the ratio of gene transcripts of Mitf with exon 6a to that of Mitf 
without exon 6a by PCR-RFLP analyses; the ratios of Mitf-A and Mitf-J were relatively 
constant during myogenesis (Fig. 1G). 
 
Disruption of Mitf expression inhibits myotube formation by blocking increased 
expression of p21 and Itga9 induction 
To clarify the roles of Mitf in myogenesis, we evaluated effects of decreased expression 
of Mitf, which was achieved by transfection with siRNA for Mitf (Supplementary Fig. 
2A, lanes 2 and 3, and B). Transfection of siRNA for common Mitf effectively 
decreased the emergence of multinucleated myotubes on day 6, as compared with GFP 
(Fig. 2A). Knockdown of Mitf-A also blocked the formation of thick myotubes (Fig. 2B, 
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Supplementary Fig. 2C). Morphological analyses on day 6 indicated that the number of 
multinucleated cells, which were defined as cells with more than 3 nuclei, was 
significantly decreased by transfection of siRNA for Mitf (Fig. 2C). We also evaluated 
the differentiated myotubes in detail; knockdown of Mitf increased the proportion of 
myotubes with 3 to 5 nuclei, but decreased that of myotubes with more than 6 nuclei 
(Fig. 2D). Similar results were also obtained in C2C12 cells transfected with siRNA for 
Mitf-A (Supplementary Fig. 3). Furthermore, Mitf knockdown decreased the expression 
of Myhc, a myotube-specific protein [3-5], in C2C12 cells on day 8 (Fig. 2E, lanes 1 
and 2). These results suggest that Mitf is required not only for myoblast-myoblast fusion 
but also for maturation of nascent myotubes. We also examined effects of forced Mitf 
expression on myotube formation; the expression did not enhance myogenesis (data not 
shown). 
 
Molecular bases of decreased myotube formation by Mitf knockdown were then 
explored. Myogenesis is regulated through modulation of the expression and activity of 
MRFs [29, 30]; however, gene transcript levels of Myf5, Myod, Myogenin and Mrf4 
were unchanged by Mitf knockdown, suggesting that impairment of myogenesis 
resulting from Mitf knockdown is not due to altered expression of MRFs (Fig. 3A-D). 
 
Other than MRFs, several molecules related to cell attachment and fusion, such as 
Adam12, Calpastatin, Caveolin3, Cdh15, Ctsb, Itga3, Itga4, Itga6, Itga9, Itgb1, Myof, 
and v-Cam1 are known to regulate myotube differentiation [2, 31-34]. In addition, the 
cDNA microarray database (http://www.ncbi.nlm.nih.gov/geo/) indicated that the 
expressions of Ccna2, Itga5, p21, p57, Ptger4, Rb1, and Vcl increased with 
differentiation. In view of Mitf as a transcription factor, we expected that Mitf is 
involved in myogenesis through transcriptional activation of these 
myogenesis-regulating genes. Thus, the effects of decrease in Mitf expression on the 
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expression level of these genes were explored. We found that gene transcript levels of 
p21 and Itga9 after differentiation stimulation were decreased by transfection of siRNA 
for common Mitf; expression of p21 was increased in response to differentiation 
stimulation, and Mitf knockdown blocked the increased expression of p21 (Fig. 3E). 
Significant expression of Itga9 was detected after day 4, and the expression level was 
decreased by transfection of siRNA for Mitf (Fig. 3F). Decreased expression of p21 and 
Itga9 was also detected in Mitf-A-knockdown cells (Supplementary Fig. 4). Gene 
transcript levels of the other genes were unaffected by Mitf knockdown (Supplementary 
Fig. 5). 
 
In a C2C12 myogenesis cell model, not all myoblasts not fuse into myotubes; 
co-existence of proliferating myoblasts and myotubes is detected after differentiation 
stimulation [35-37]. We separated the myotube-rich fraction by limited trypsinization to 
explore cells affected by Mitf knockdown. Although Myhc2a expression was not 
significantly different between the myotube fraction and the residual cell fraction in 
control cells (Fig. 4A), Myhc2b and Myhc2x were predominantly expressed in the 
myotube fraction as expected (Fig. 4B and C). Expression of Myhc2x in the myotube 
fraction was significantly lower in Mitf-knockdown cells than in control cells, whereas 
that of Myhc2a in the myotube fraction was higher in the Mitf-knockdown cells. The 
Myhc2b expression in the myotube fraction was comparable between in control cells 
and in Mitf-knockdown cells. Considering that Myhc2x was the major isoform of type 2 
Myhc (> 93%) (Fig. 4D), total expression of Myhc constituting of fast-twitch myofibers 
was largely limited to the myotube fraction, and was decreased by Mitf knockdown; the 
latter was consistent with the results on Myhc expression at the protein level (Fig. 2E). 
 
The extent of the decreased expression of Mitf resulting from knockdown of Mitf was 
comparable between the myotube fraction and the residual cell fraction, indicating 
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effective inhibition of Mitf expression in both myoblasts and myotubes (Fig. 5A). 
Expression of p21 was significantly higher in the myotube fraction than in the residual 
cell fraction (Fig. 5B). Knockdown of Mitf equally decreased the expression of between 
the two fractions. Expression of Itga9 was also significantly higher in the myotube 
fraction (Fig. 5C). Similar to the expression of p21, Mitf knockdown down-regulated the 
expression of Itga9 in both fractions. 
 
Cell cycle exit in response to differentiation stimulation is a prerequisite for myotube 
formation [2]; p21, a cyclin-dependent kinase inhibitor inducing cell cycle exit, plays a 
role in post-mitotic myogenesis, although it also maintains anti-apoptotic states in 
differentiated myocytes [1]. To link the decreased Mitf-induced inhibition of myotube 
formation and blockage of p21 induction, effects of the decreased Mitf expression on 
BrdU uptake were next examined; BrdU uptake was significantly increased by 
transfection of siRNA for Mitf on day 4-6 (Fig. 5A). Knockdown of p21, however, did 
not affect BrdU uptake (Fig. 5B). Similar to Mitf knockdown, decreased expression of 
p21 inhibited emergence of maturated and thick myotubes (Fig. 5C). In addition, it 
significantly decreased the number of multinucleated cells (Fig. 5D), and increased and 
decreased the proportion of myotubes with 3 to 5 nuclei and those with more than 6 
nuclei, respectively (Fig. 5E). 
 
We next explored the effects of Itga9 knockdown on myotube formation. The 
morphology of cells transfected with siRNA for Itga9 indicated that, compared to 
control cells, thinner myotubes were evident by Itga9 knockdown, suggesting that Itga9 
is required for myotube maturation (Fig. 6A), which was verified by morphometry. The 
multinucleated cell number itself was not affected by knockdown of Itga9 (Fig. 6B), but 
the proportion of the number of myotubes with 3-5 nuclei in a cell to that of total 
myotubes was significantly increased, and that with more than 6 nuclei was decreased 
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(Fig. 6C). Consistent with the results, knockdown of Itga9 gene resulted in the 




Here, we demonstrate that 1) A isoform of Mitf mRNA is abundant in the skeletal 
muscle, 2) Mitf-A expression increased with progression of myogenesis, 3) knockdown 
of Mitf mRNA disrupts myotube formation through inhibition of myoblast-myoblast 
fusion and subsequent myoblast-myotube fusion, but does not affect the expression of 
MRFs, and 4) expression of p21, a cyclin-dependent kinase inhibitor, and Itga9 is 
regulated by Mitf in a stage-dependent manner for appropriate myogenesis. The present 
results indicate a novel role of a tissue-restricted transcription factor Mitf in the 
regulation of myogenesis, which is probably mediated by an MRF-independent 
pathway. 
 
Mitf regulates myogenesis in multiple steps. Expression of p21 and Itga9 was 
modulated by decreased expression of Mitf; down-regulation of p21 expression resulting 
from knockdown of Mitf mRNA was limited to post-differentiation, and significant 
Itga9 expression was detected just after differentiation stimulation. Considering that 
significant expression of Mitf was detected prior to differentiation stimulation, the gene 
expression of p21 and Itga9 could not be regulated by Mitf alone, but in concert with 
Mitf and as yet unidentified factor(s). Transfection of siRNA for Mitf resulted in 
down-regulated expression of Mitf both in myoblasts and myotubes. Thus, the precise 
mechanism of how Mitf regulates not only p21 in myoblasts and myotubes but also 
Itga9 expression in myotubes remains unclear. Since Mitf binds to the E-box (CAnnTG) 
located in the 5'-untranslated region and activates transcription [6-8], Mitf may directly 
regulate transcription of p21 and Itga9. Alternatively, it is possible that a factor 
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regulated by Mitf in myoblasts acts as a regulator to induce p21 or Itga9 in myotubes. 
 
A target gene of Mitf was Itga9. Among members of the integrin family, Itga3, 4, 6 and 
9 have been suggested to regulate myogenesis [2, 31, 33, 34]. Transcription of Itga4 
was activated through Mitf binding to the E-box located in the 5'-untranslated region in 
mast cells [38]. In the present study, however, Itga4 mRNA was not decreased but 
rather increased by transfection of siRNA for Mitf in C2C12 cells (Supplementary Fig. 
2H), suggesting that transcription by Mitf is regulated in a cell context-dependent 
manner. In addition, Mitf knockdown did not affect the expression level of Itga3 and 6 
(Supplementary Fig. 2G and J). In a study using a human mononucleated myogenic
 
precursor cell culture system, addition of anti-INTEGRIN 91 antibody to the culture 
medium decreased the proportion of nuclei included in large myotubes (≥5 nuclei), 
whereas the proportion of nuclei incorporated in small myotubes (2-4 nuclei) was 
unchanged [33]. In the present study using a murine myogenesis model, transfection 
with siRNA for Itga9 decreased the proportion of large myotubes (6 nuclei) and 
increased that of small myotubes (3-5 nuclei), but did not affect the number of 
multinucleated cells. Taking these results together, Itga9 is suggested to promote the 
growth of preformed myotubes rather than the formation of nascent myotubes during 
myogenesis. 
 
Effects of knockdown of Mitf mRNA partly overlapped but were distinct from those of 
Itga9 knockdown; the number of multinucleated cells was decreased by Mitf 
knockdown. This suggests that Mitf is involved in both myoblast-myoblast fusion and 
subsequent maturation of nascent myotubes. It is possible that Mitf regulates 
myoblast-myoblast fusion through the increase in p21 expression; regulatory expression 
of p21 by Mitf has also been shown in melanocytes [39]. Cell cycle inhibition and 
apoptosis of myoblasts precede to myoblast-myoblast fusion, and both processes are 
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necessary for the cell fusion [1]. p21 is principally involved as a molecule to establish 
post-mitotic and apoptosis-resistant states [1]; BrdU uptake was not detected in 
p21-positive myoblasts [40], and forced expression of p21 but not inactive p21 inhibited 
apoptosis of C2C12 myoblasts [41]. In fact, p21 knockdown decreased the myotube 
number and increased proportion of small myotubes, suggesting that p21 expression is 
required for efficient myoblast-myoblast fusion. 
 
Knockdown of p21 did not increase BrdU uptake on day 4 and 6; it may be offset 
effects of the cell growth inhibition and the anti-apoptotic activity. In view of significant 
inhibition of BrdU uptake in Mitf-knockdown cells on day 4 and 6, Mitf regulates 
expression and activity of additional molecule(s) unidentified in this study. 
 
Bharti et al. [19] revealed that Mitf-A and -J are expressed throughout eye development 
in both retina and pigment epithelium, whereas expression of Mitf-D and -M was limited 
to pigment epithelium. In addition, Mitf-H was preferentially found in pigment 
epithelium with temporal expression profile. Unlike the eye development, the 
proportion of expressed Mitf isoforms, i.e., Mitf-A and Mitf-J was almost constant 
during myogenesis of C2C12 cells, although total Mitf expression was increased with 
progression of myogenesis (Fig. 1C). Thus, expression of Mitf isoforms is 
tissue-specific and stage-dependent. In view of different activity as transcription factors 
between the isoforms [15-18], regulation on the use of alternative promoter must be 
clarified in future studies. 
 
Mitf encoded by the mutant mi allele deletes one of four consecutive arginines in the 
basic domain, and acts as a dominant-negative mutant [9, 27, 42]. The mi/mi mutant 
mice exhibited the pleiotropic effects of microphthalmia, depletion of pigment in both 
hair and eyes, and osteopetrosis resulting from defects of osteoclastogenesis [9, 14]. In 
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addition to these phenotype alterations, Katayama et al. [43] recently showed that 
masseter muscle development was disrupted in mi/mi mutant mice; they speculated that 
the disorder is a secondary event related to abnormal tooth formation related to 
osteoclast dysfunction; however, in view of the present results showing direct inhibition 
of myogenesis by decreased expression of Mitf, muscle development itself may be 
disturbed in mi/mi mice. 
 
The present study indicates significant expression of Mitf in the skeletal muscle from 
re-evaluation of tissue distribution of Mitf by sensitive qRT-PCR analyses. Evaluation 
of Mitf activity clarifies its role as a positive regulator during myogenesis. Because Mitf 
is expressed also in other tissues with a variation of expression level, future studies 
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Fig. 1. Mitf expression is highly expressed in the skeletal muscle and increases 
with progression of myogenesis in C2C12 cells 
(A) Mitf expression in various tissues was measured by qRT-PCR. Mitf expression was 
expressed as a ratio to -actin expression. Data are shown as the mean  SE. (B) 
Expression of Mitf isoform differing with transcriptional initiation site in the skeletal 
muscle was identified by qRT-PCR using isoform-specific 5’-primer and 3’-primer 
spanning the common Mitf. The percentage of the expression of each Mitf isoform to 
that of total Mitf was calculated. Data are shown as the mean  SE. (C) C2C12 
myoblasts were cultured to confluence (day 0) in growth medium, followed by culture 
in differentiation medium. Time-course changes in expression of Mitf isoform differing 
with transcriptional initiation site during myogenesis were examined in C2C12 cells. 
Mitf expression was expressed as a ratio to Gapdh expression. Data are shown as the 
mean  SE (n = 2). (D) Expression of Mitf in the skeletal muscle. Protein extracted 
from heart, thigh muscle and C2C12 cells was subjected to Western blot analyses to 
examine Mitf expression at the protein level. A representative result of Western blot is 
shown. In the heart, Mitf-H as well as Mitf-A is mainly expressed shown in (B). Note 
that calculated molecular weight of Mitf-H and Mitf-A is 56.8 k and 58.6 k, respectively. 
(E) Time-course changes in expression of Mitf protein were examined during 
myogenesis of C2C12 cells. A representative result of Western blot is shown. (F) 
Immunolocalization of Mitf in C2C12 cells. C2C12 myoblasts were fixed and reacted 
with (right) or without (left) mouse monoclonal anti-Mitf antibody. Subsequently, cells 
were reacted with anti-mouse IgG antibody, and the antibody was visualized. A 
representative cell staining is shown. (G) The ratio of exon 6a-containing Mitf isoforms 
(exon 6a + 6b) to non-exon 6a-containing isoforms (exon 6b) was evaluated in C2C12 
cells. PCR products of Mitf -A and -J were digested by Hinf I, and DNA fragments with 
or without exon 6a were separated by PAGE. A photograph of a representative gel 
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stained with ethidium bromide is shown. 
 
Fig. 2. Mitf expression is required for efficient myotube formation 
C2C12 cells were transfected with siRNA for GFP as a control, common Mitf or Mitf-A 
every 2 days after day -2. (A) Effect of Mitf knockdown on myogenesis was evaluated. 
Representative phase-contrast images on day 0, 2, 4, and 6 are presented. (B) Role of 
Mitf-A was examined. Representative cells stained by Giemsa solution on day 6 are 
presented. (C and D) Myotube formation was evaluated in Mitf-knockdown C2C12 cells. 
Cells were transfected with siRNA for GFP as a control or Mitf, and morphology was 
evaluated on day 6. After staining with Giemsa solution, cell number and the number of 
nuclei were calculated. (C) Ratio of multinucleated cell number to total cell number was 
calculated, and the ratio of cells transfected with siRNA for GFP was set to 1. (D) 
Number of cells with 3 to 5, 6 to 10 or >11 nuclei were counted, and percentage to total 
multinucleated cells is shown. Data are shown as the mean  SE (n = 6). * and **: P < 
0.05 and P <0.01, respectively, as compared to control. (E) Expression of Myhc in 
response to transfection of siRNA for GFP as a control, Mitf or Itga9 in C2C12 cells on 
day 8 was examined by Western blot analyses. Subsequently, the membranes were 
reprobed with anti--actin antibody. 
 
Fig. 3. p21 and Itga9 are targets of Mitf for progression of myogenesis 
C2C12 cells were transfected with siRNA for GFP as a control or common Mitf every 2 
days after day -2. Gene expression of Myf5 (A), Myod (B), Myogenin (C), Mrf4 (D), 
p21 (E) and Itga9 (F) was quantified by qRT-PCR. The expression was normalized to 
Gapdh expression. The expression in cells on day -2 was set to 1 for Myf5, Myod, 
Myogenin, Mrf4 and p21, and that in cells transfected with siRNA for GFP on day 4 




Fig. 4. Knockdown of Mitf in myoblasts and myotubes down-regulates 
expression of Myhc2x 
C2C12 cells were transfected with siRNA for GFP as a control or common Mitf every 2 
days after day -2. On day 7, multinucleated myotubes were separated from the residual 
cells by limited trypsinization. Expression of Myhc2a (A), Myhc2b (B) and Myhc2x (C) 
was quantified by qRT-PCR, and normalized to Gapdh expression. The expression in 
residual cells after limited trypsinization in the control group was set to 1. (D) The 
percentage of the expression of each Myhc isoform to that of total type II Myhc was 
calculated. Data are shown as the mean  SE (n = 3). a, b, c, d: Means that do not have a 
common letter on the bar differ significantly (P < 0.05). 
 
Fig. 5. Knockdown of Mitf in myoblasts and myotubes down-regulates 
expression of p21 and Itga9 
C2C12 cells were transfected with siRNA for GFP as a control or common Mitf every 2 
days after day -2. On day 7, multinucleated myotubes were separated from the residual 
cells by limited trypsinization. Expression of Mitf (A), p21 (B), and Itga9 (C) was 
quantified by qRT-PCR, and normalized to Gapdh expression. The expression in 
residual cells after limited trypsinization in the control group was set to 1. Data are 
shown as the mean  SE (n = 3). a, b, c, d: Means that do not have a common letter on 
the bar differ significantly (P < 0.05). 
 
Fig. 6. p21 is involved in Mitf-mediated myogenesis 
(A and B) Role of Mitf and p21 in BrdU uptake in C2C12 cells was evaluated. (A) Cells 
were transfected with siRNA for GFP as a control or common Mitf every 2 days after 
day -2, and BrdU uptake was examined on day -1, 0, 4 and 6. BrdU uptake in control 
cells on day -1 was set to 100. (B) Cells were transfected with siRNA for GFP or p21 
every 2 days after day 2, and BrdU uptake was examined on day 4 and 6. Data are 
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shown as the mean  SE (n = 3-4). **: P <0.01, as compared to control. (C-E) Role of 
p21 in myogenesis was evaluated. Cells were transfected with siRNA for GFP or p21 
every 2 days after day 2. (C) Representative cells stained by Giemsa solution on day 6 
are shown. (D and E) Myotube formation was evaluated in p21-knockdown C2C12 cells. 
After staining cells with Giemsa solution on day 6, cell number and the number of 
nuclei were calculated. (D) Ratio of multinucleated cell number to total cell number was 
calculated, and the ratio of cells transfected with siRNA for GFP was set to 1. (E) 
Number of cells with 3 to 5, 6 to 10 or >11 nuclei was counted, and percentage to total 
multinucleated cells is shown. Data are shown as the mean  SE (n = 4). * and **: P < 
0.05 and P <0.01, respectively, as compared to control. 
 
Fig. 7. Itga9 are involved in Mitf-mediated myogenesis 
(A-C) Role of Itga9 in myogenesis was evaluated. Cells were transfected with siRNA 
for GFP or Itga9 every 2 days after day -2. (A) Representative cells stained by Giemsa 
solution on day 6 are shown. (B and C) Myotube formation was evaluated in 
Itga9-knockdown C2C12 cells. After staining cells with Giemsa solution on day 6, cell 
number and the number of nuclei were calculated. (B) Ratio of multinucleated cell 
number to total cell number was calculated, and the ratio of cells transfected with 
siRNA for GFP was set to 1. (C) Number of cells with 3 to 5, 6 to 10 or >11 nuclei was 
counted, and percentage to total multinucleated cells is shown. Data are shown as the 
mean  SE (n = 4). **: P <0.01, as compared to control. 
 
 
Supplementary Fig. 1 Time-course changes in expression of Gapdh and -actin 
during myogenesis of C2C12 cells 
C2C12 myoblasts were cultured to reach confluence (day 0) in growth medium, 
followed by culture in differentiation medium. Expression of Gapdh and -actin using 
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cDNA prepared from 5 ng of total RNA was quantified by qRT-PCR, and normalized to 
Hprt1 expression. The expression on day 0 was set to 1. Data are shown as the mean  
SE (n = 2). 
 
Supplementary Fig. 2 Effects of Mitf knockdown on Mitf expression in C2C12 
cells 
(A) C2C12 cells were transfected with siRNA for GFP as a control (c, lane 2) or 
common Mitf (M, lane 3) for 2 days. Western blot analyses were performed to examine 
Mitf expression. As a positive control, lysates of B16 melanoma cells were used (lane 
1). B16 cells express mainly Mitf-M, whereas C2C12 cells predominantly express 
Mitf-A as shown in Fig. 1C. Note that calculated molecular weight of Mitf-M (46.8 k) 
is smaller than that of Mitf-A (58.6 k). (B and C) C2C12 cells were transfected with 
siRNA for GFP as a control, common Mitf or Mitf-A every 2 days after day -2. Gene 
expression of common Mitf (B) and Mitf-A (C) was quantified by qRT-PCR. The 
expression was normalized to Gapdh expression. The expression in cells on day -2 was 
set to 1. Data are shown as the mean  SE (n = 2). 
 
Supplementary Fig. 3 Impaired myotube formation in C2C12 cells transfected 
with siRNA for Mitf-A 
C2C12 cells were transfected with siRNA for GFP as a control or Mitf-A every 2 days 
after day -2. (A and B) Myotube formation was evaluated in Mitf-A-knockdown C2C12 
cells. Cells were transfected with siRNA for GFP as a control or Mitf-A, and 
morphology was evaluated on day 6. After staining with Giemsa solution, cell number 
and the number of nuclei were calculated. (A) Ratio of multinucleated cell number to 
total cell number was calculated, and the ratio of cells transfected with siRNA for GFP 
was set to 1. (B) Number of cells with 3 to 5, 6 to 10 or >11 nuclei were counted, and 
percentage to total multinucleated cells is shown. Data are shown as the mean  SE (n = 
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6). * and **: P < 0.05 and P <0.01, respectively, as compared to control. 
 
Supplementary Fig. 4 Decreased expression of p21 and Itga9 in C2C12 cells 
transfected with siRNA for Mitf-A 
C2C12 cells were transfected with siRNA for GFP as a control or Mitf-A every 2 days 
after day -2. Gene expression of p21 (A) and Itga9 (B) was quantified by qRT-PCR. 
The expression was normalized to Gapdh expression. The expression in cells 
transfected with siRNA for GFP on day -2 was set to 1. Data are shown as the mean  
SE (n = 2). 
 
Supplementary Fig. 5 Effects of Mitf knockdown on gene expression in C2C12 
cells 
C2C12 cells were transfected with siRNA for GFP as a control or common Mitf every 2 
days after day -2. Gene expression of Adam12 (A), Calpastatin (B), Caveolin3 (C), 
Ccna2 (D), Cdh15 (E), Ctsb (F), Itga3 (G), Itga4 (H), Itga5 (I), Itga6 (J), Itgb1 (K), 
Myof (L), p57 (M), Ptger4 (N), Rb1 (O), v-Cam1 (P), and Vcl (Q) was quantified by 
qRT-PCR. The expression was normalized to Gapdh expression. The expression in cells 
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Table 1. Oligonucleotide PCR primers for qRT-PCR 
 Oligonucleotide GenBank 
 5’-primer 3’-primer accession number 
Mitf: 
 Common Mitf 5’-GCCTTGCAAATGGCAAATAC-3’ 5’-GCTGGACAGGAGTTGCTGAT-3’  
Mitf-A   5’-GAGGAGTTTCACGAAGAACC-3’      5’-GCTGGCGTAGCAAGATGCGTGA-3’    NM_001113198 
Mitf-H   5’-GAGGAGTTTCACGAAGAACC-3’      5’-GCTGGCGTAGCAAGATGCGTGA-3’    NM_001178049 
Mitf-J 5’-CCGTGTCTCTGGGCATCTGAAG-3’ 5’-GCTGGCGTAGCAAGATGCGTGA-3’ AY632575 
Mitf-M     5’- ATGCTGGAAATGCTAGAATACAG-3’ 5’-CATACCTGGGCACTCACTCTC-3’    NM_008601 
 
Myogenic regulatory factors: 
 Myf5 5’-GCCAGTTCTCCCCTTCTGAGTA-3’ 5’-TGGTCCCCAAACTCATCCTCT-3’ NM_008656 
 Myod1 5’-GTGGCAGCGAGCACTA-3’ 5’-GGGCCGCTGTAATCCATC-3’ NM_010866 
 Myogenin 5’-AGAAGCGCAGGCTCAAGAAA-3’ 5’-ATCTCCACTTTAGGCAGCCG-3’ NM_031189 
Mrf4 5’-GGGCCTCGTGATAACTGCT-3’ 5’-AAGAAAGGCGCTGAAGACTG-3’ NM_008657 
 
Myosin heavy chains: 
 Myhc2a 5’-AAAGCTCCAAGGACCCTCTT-3’ 5’-AGCTCATGACTGCTGAACTCAC-3’ NM_ 001039545 
 Myhc2b 5’-CCGAGCAAGAGCTACTGGA-3’ 5’-TGTTGATGAGGCTGGTGTTC-3’ NM_010855 
 Myhc2x 5’-TCGCTGGCTTTGAGATCTTT-3’ 5’-CGAACATGTGGTGGTTGAAG-3’ NM_ 030679 
 
Target candidates: 
Adam12 5’-CAGAGCATCCCAGCCAAG-3’ 5’-CAGGCTGAGGATCAGGTCTC-3’ NM_007400 
Calpastatin 5’-CCTTCAGCTGGTGGAGAGAG-3’ 5’-GCTGGTGTGAATGGTTTCTG-3’ NM_009817 
Caveolin3 5’-CACAAGGCTCTGATCGCCTC-3’ 5’-TCCGTGTGCTCTTCGGTCA-3’ NM_007617 
Ccna2 5’-CTTGGCTGCACCAACAGTAA-3’ 5’-CAAACTCAGTTCTCCCAAAAACA-3’ NM_009828 
Cdh15 5’-TGACATTGCCAACTTCATCAG-3’ 5’-GATGAGAGCTGTGTCGTAGGGAG-3’ NM_007662 
Ctsb 5’-AAGCTGTGTGGCACTGTCCTG-3’ 5’-GATCTATGTCCTCACCGAACGC-3’ NM_007798 
Itga3 5’-CATCAACATGGAGAACAAGACC-3’ 5’-CCAACCACAGCTCAATCTCA-3’ NM_013565 
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Itga4 5’-ACCAGACCTGCGAACAGC-3’ 5’-CCCCCAGCCACTGGTTAT-3’ NM_010576 
Itga5 5’-TACTCTGTGGCTGTGGGTGA-3’ 5’-GCCATTAAGGACGGTGACAT-3’ NM_010577 
Itga6 5’-GGTTGAGAGGCCATGAAAAG-3’ 5’-TTCTTTTGTTCTACACGGACGA-3’ NM_008397 
Itga9 5’-TGATGCCAACGTGTCCTTTA-3’ 5’-GAAATGCCCATCTCCTCCT-3’ NM_133721 
Itgb1 5’-ATGCAGGTTGCGGTTTGT-3’ 5’-CATCCGTGGAAAACACCAG-3’ NM_010578 
Myof 5’-CATTACTGGCTTCTAAGCTGTCG-3’ 5’-AAATTTACTCCACCAGTCAACG-3’ NM_001099634 
p21 5’-TGGGCCCGGAACATCTC-3’ 5’-TGCGCTTGGAGTGATAGAAA-3’ NM_007669 
p57 5’-CAGGACGAGAATCAAGAGCA-3’ 5’-TGCGCTTGGCGAAGAAGT-3’ NM_009876 
Ptger4 5’-TCCAGATGGTCATCTTACTCAT-3’ 5’-TAACTGGTTAATGAACACTCGCA-3’ NM_001136079 
Rb1 5’-GCTGCAAATACAGAGACACAAGCAG-3’ 5’-CGGAGATATGCTAGACGGTACACTT-3’ NM_009029 
v-Cam1 5’-TGATTGGGAGAGACAAAGCA-3’ 5’-AACAACCGAATCCCCAACT-3’ NM_011693 
Vcl 5’-GATAGCTGCTCTGACCTCTAA-3’ 5’-TAGTGCCGTCGCCACTTGTTT-3’ NM_009502 
 
Reference genes: 
 -actin 5’-CTAAGGCCAACCGTGAAAAG-3’ 5’-ACCAGAGGCATACAGGGACA-3’ X03672 
  Gapdh          5’-CGTGTTCCTACCCCCAATGT-3’         5’-TGTCATCATACTTGGCAGGTTTCT-3’    NM_008084 
